Get the Stockscreener App
80.39
2.12%
-1.74
After Hours:
80.39
Ani Pharmaceuticals Inc stock is traded at $80.39, with a volume of 413.11K.
It is down -2.12% in the last 24 hours and down -7.88% over the past month.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
See More
Previous Close:
$82.13
Open:
$82.32
24h Volume:
413.11K
Relative Volume:
1.13
Market Cap:
$1.81B
Revenue:
$747.40M
Net Income/Loss:
$-12.60M
P/E Ratio:
-104.58
EPS:
-0.7687
Net Cash Flow:
$105.18M
1W Performance:
-1.69%
1M Performance:
-7.88%
6M Performance:
+29.41%
1Y Performance:
+42.13%
1-Day Range:
$79.98
$83.00
1-Week Range:
$79.98
$83.60
52-Week Range:
$52.50
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
Ani Pharmaceuticals Inc
Sector
Phone
(218) 634-3500
Address
210 MAIN STREET WEST, BAUDETTE, MN
Compare ANIP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
80.39 | 1.84B | 747.40M | -12.60M | 105.18M | -0.7687 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | H.C. Wainwright | Buy |
| Mar-14-25 | Initiated | Jefferies | Buy |
| Mar-12-25 | Initiated | JP Morgan | Overweight |
| Dec-11-24 | Initiated | Leerink Partners | Outperform |
| Oct-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-15-24 | Initiated | CapitalOne | Overweight |
| Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Sep-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-02-21 | Initiated | Truist | Buy |
| May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
| Jul-31-17 | Initiated | Canaccord Genuity | Buy |
| Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-23-16 | Initiated | Raymond James | Strong Buy |
| May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
| Nov-13-15 | Initiated | Standpoint Research | Buy |
| Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
| Aug-04-15 | Reiterated | ROTH Capital | Neutral |
| Jul-31-15 | Reiterated | Oppenheimer | Outperform |
| Jul-15-15 | Reiterated | ROTH Capital | Neutral |
| Jun-23-15 | Reiterated | Oppenheimer | Outperform |
| May-18-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Reiterated | Oppenheimer | Outperform |
| Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-26-15 | Reiterated | ROTH Capital | Buy |
| Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
Ani Pharmaceuticals Inc Stock (ANIP) Latest News
ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells $32,928.00 in Stock - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Implied Volatility Surging for ANI Pharmaceuticals Stock Options - Nasdaq
ANI Pharmaceuticals Director Sold $146K In Company Stock - Benzinga
ANI Pharmaceuticals (NASDAQ:ANIP) Director Sells $146,070.00 in Stock - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) Coverage Initiated by Analysts at Barclays - MarketBeat
Barclays Initiates ANI Pharmaceuticals at Overweight With $100 Price Target - marketscreener.com
ANI Pharmaceuticals (ANIP): Has the Recent Share Price Pullback Created a Valuation Opportunity? - Yahoo Finance
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by JPMorgan Chase & Co. - MarketBeat
Kennedy Capital Management LLC Reduces Stake in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
The Bull Case For ANI Pharmaceuticals (ANIP) Could Change Following Governance Shake-Up And FutureVision Launch – Learn Why - Sahm
Is ANI Pharmaceuticals Inc. (BSFA) stock a buy for dividend portfoliosPortfolio Performance Report & Low Drawdown Investment Strategies - Newser
ANI Pharmaceuticals (ANIP): Valuation Check After Governance Shake-Up and New Rare Disease Strategy Moves - Sahm
Sio Capital Management LLC Buys 25,625 Shares of ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Russell Investments Group Ltd. Decreases Stake in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Can ANI Pharmaceuticals Inc. (BSFA) stock reach $200 price target2025 Market Outlook & Capital Efficient Trade Techniques - Newser
ANI Pharmaceuticals chairman Patrick Walsh to retire, Thomas Haughey to succeed - MSN
ANI Pharmaceuticals Announces Leadership Transition in Board - MSN
ANI Pharmaceuticals establishes FutureVision Advisory Council By Investing.com - Investing.com Nigeria
ANI Pharmaceuticals Announces Formation of FutureVision Advisory Council to Help Strategically Guide Ophthalmology and Retina Franchise - marketscreener.com
ANI Pharmaceuticals, Inc. $ANIP Stock Position Lessened by Virtus Advisers LLC - MarketBeat
ANI Pharmaceuticals establishes FutureVision Advisory Council - Investing.com
Loomis Sayles & Co. L P Has $13.47 Million Stake in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals Announces Formation of 'FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise - The Manila Times
ANI Pharmaceuticals Announces Formation of “FutureVision - GlobeNewswire
ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise - Sahm
ANI Pharmaceuticals (ANIP) Stock Analysis Report | Financials & Insights - Benzinga
Can ANI Pharmaceuticals Inc. (BSFA) stock stage a strong rebound this quarter2025 Momentum Check & Consistent Profit Trading Strategies - Newser
ANI Pharmaceuticals chairman Walsh to retire, Haughey elected successor By Investing.com - Investing.com Australia
ANI Pharmaceuticals announces board transition - marketscreener.com
ANI Pharmaceuticals Announces Board Transition - TradingView
ANI Pharmaceuticals' Chairman Patrick Walsh to Retire; Thomas Haughey Named Successor - marketscreener.com
ANI Pharmaceuticals chairman Walsh to retire, Haughey elected successor - Investing.com India
ANI Pharmaceuticals Announces Board Changes - TradingView
ANI Pharmaceuticals Announces Leadership Transition as Patrick D. Walsh Steps Down as Chairman, Thomas J. Haughey Elected as Successor - Quiver Quantitative
Elevation Point Wealth Partners LLC Invests $245,000 in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Does Recent Pipeline News Signal a New Opportunity for ANI Pharmaceuticals Stock in 2025? - Yahoo Finance
First Week of July 2026 Options Trading For ANI Pharmaceuticals (ANIP) - Nasdaq
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Dynamic Technology Lab Private Ltd Makes New Investment in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Will ANI Pharmaceuticals Inc. stock attract ESG investorsJuly 2025 EndofMonth & Community Trade Idea Sharing - moha.gov.vn
Market Catalysts: Can ANI Pharmaceuticals Inc. stock deliver consistent earnings growthJuly 2025 Macro Moves & Real-Time Volume Analysis - BỘ NỘI VỤ
ANI Pharmaceuticals (ANIP): Assessing Valuation After Rare Disease Revenue Surges on Cortrophin Gel Demand - Sahm
ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Universal Beteiligungs und Servicegesellschaft mbH Has $4.22 Million Holdings in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
CapEx per share of ANI Pharmaceuticals, Inc. – LSX:A1W15D - TradingView
Envestnet Asset Management Inc. Raises Stock Holdings in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals, Inc. (ANIP) Stock forecasts - Yahoo Finance UK
What ANI Pharmaceuticals (ANIP)'s Rare Disease Revenue Surge Means for Shareholders - Sahm
ANI Pharmaceuticals, Inc. $ANIP Shares Acquired by Intech Investment Management LLC - MarketBeat
ANIP SEC FilingsAni Pharmaceutic 10-K, 10-Q, 8-K Forms - Stock Titan
Ani Pharmaceuticals Inc Stock (ANIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.48%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):